Status:
COMPLETED
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
Lead Sponsor:
Henry Ford Health System
Conditions:
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Eligibility:
All Genders
18-80 years
Brief Summary
For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option. Patients after SCT o...
Detailed Description
so for participants with SCT or CART who decide to get their vaccines, the investigators will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days...
Eligibility Criteria
Inclusion
- any SCT or CART post COVID vaccine
Exclusion
- none
Key Trial Info
Start Date :
March 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 2 2024
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04723706
Start Date
March 19 2021
End Date
January 2 2024
Last Update
April 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Health System
Detroit, Michigan, United States, 48202